Double blinded, randomized, Priorix- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability in healthy volunteers.

Trial Profile

Double blinded, randomized, Priorix- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability in healthy volunteers.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Chikungunya virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix)
  • Indications Chikungunya virus infections
  • Focus Pharmacodynamics
  • Sponsors Themis Bioscience
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Jun 2018.
    • 10 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
    • 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top